



an Open Access Journal by MDPI

Cholesterol Metabolism in Cancers and Therapeutic Innovations

Guest Editors:

Dr. Marc Poirot

Cholesterol Metabolism and Therapeutic Innovations Team, UMR 1037 INSERM-Toulouse University, Toulouse, France

Dr. Sandrine Silvente-Poirot

Cholesterol Metabolism and Therapeutic Innovations Team, CRCT UMR1037 INSERM, Universite de Toulouse, Toulouse, France

Deadline for manuscript submissions: closed (30 December 2018)

Message from the Guest Editors

This Special Issue on cholesterol metabolism in cancer and therapeutic innovations will focus on strategies for improving cancer treatment efficacy in vitro or in vivo. Of particular interest will be manuscripts revealing the contribution of cholesterol metabolism dysregulation in oncogenesis. Manuscripts describing the pharmacological characterization of natural or synthetic drug candidates targeting sterol biosynthesis and metabolism directly or indirectly are encourage. This Special Issue will include original research, review articles, commentaries, and editorials discussing cholesterol metabolism deregulations and targeting in cancers. Topics of interest for this Special Issue include, but are not limited to, the keywords listed below.

• oxysterol, oxyphytosterol, steroidal alkaloids, cholesterol biosynthesis, LDL, HDL, CD36, SRB1, cell proliferation, metastasis, antitumor immune response









an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine* (*miscellaneous*))

Contact Us

Biomedicines Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/biomedicines biomedicines@mdpi.com X@Biomed_MDPI